> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Scynexis Yeast Infection Drug Approved
- URL: https://www.fdaweb.com/scynexis-yeast-infection-drug-approved/
- Published: 2021-06-02T12:00:00.000Z
- Updated: 2026-09-14T17:01:20.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5149454

FDA has approved a Scynexis NDA for Brexafemme (ibrexafungerp) tablets for oral use in patients with vulvovaginal candidiasis (vaginal yeast infection). The company says it is the first approved drug in a novel antifungal class in more than 20 years. Approval was based on data from two Phase 3 studies that showed the drug demonstrated efficacy and a favorable tolerability profile in women with a yeast infection, it says.

Scynexis says ibrexafungerp is contraindicated during pregnancy and in patients with a history of hypersensitivity to the drug. Most common adverse reactions observed in clinical trials were diarrhea, nausea, abdominal pain, dizziness, and vomiting.